Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta‐analysis of randomized controlled trials

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 11, 2015-11 ,pp. : 1065-1074

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of glucagon‐like peptide‐1 receptor agonists compared to dipeptidyl peptidase‐4 inhibitors for the management of type 2 diabetes: A meta‐analysis of randomized clinical trials

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. S1, 2018-02 ,pp. : 68-76

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cardiovascular safety of the glucagon‐like peptide‐1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta‐analysis of randomized controlled trials

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 5, 2015-05 ,pp. : 505-510

John Wiley & Sons Inc

Access to resources Recommend Favorite

Utility of HbA_1c and fasting plasma glucose for screening of Type 2 diabetes: a meta‐analysis of full ROC curves

By  

DIABETIC MEDICINE, Vol. 35, Iss. 3, 2018-03 ,pp. : 317-322

John Wiley & Sons Inc

Access to resources Recommend Favorite

Factors associated with the effect-size of thiazolidinedione (TZD) therapy on HbA_1c: a meta-analysis of published randomized clinical trials

By Phatak Hemant M.   Yin Donald D.  

Current Medical Research and Opinion, Vol. 22, Iss. 11, 2006-11 ,pp. : 2267-2278

Informa Healthcare

Access to resources Recommend Favorite